Abstract

Mohammad Shakil* and Mohammad Shahid Khan

ABSTRACT

Benign prostatic hypertrophy (B.P.H) is a common condition in men above 50 years of age & is characterized by a nonmalignant enlargement of the prostate resulting from excessive cellular growth of both the glandular and the stromal elements of the gland. The clinical feature of B.P.H. includes incomplete emptying, frequency, intermittency, weak stream, straining & nocturia. Modern treatment though effective in treating symptoms has a number of side effects such as Sexual dysfunction, Postural hypotension, Asthenia, Dizziness, etc. Similarly, surgical procedures such as prostatectomy, laser treatment & transurethral resection of the prostate (TURP) are costly & associated with a high risk of complications and morbidity. Hence, there is a definite need to explore and evaluate the efficacy of Unani medicines in the management of B.P.H.